| 摘要 |
The present invention relates to a modified HGF-1K1 polypeptide (such as that shown in Seq ID No:4), and certain mutations for the disruption of an identified glycosylation site, DNA sequences encoding those proteins (such as those sequences in Seq ID NO: 5 and 6) and various methods for their production. The invention also relates to pharmaceutical compositions containing the modified HGF-1K1 polypeptides and to their use in the treatment of various diseases such as COPD, broncheolitis obliterans, acute lung injury (ALI), idiopathic pulmonary fibrosis (IPF), myocardial infarction, liver fibrosis and kidney fibrosis. |
